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Abstract Latent transforming growth factor L binding protein-
1 (LTBP1) is important in regulating the localisation and
activation of transforming growth factor L (TGFL). Three forms
of LTBP1 mRNA have previously been described, LTBP1L,
LTBP1S and LTBPv53. Here, we have analysed the LTBP1
coding sequence and identified two other spliced forms,
LTBP1v55 and LTBP1v41. LTBP1v55 is a short form of
LTBP1L which lacks 55 amino acids including two consensus
N-glycosylation sites and LTBP1v41 is a form of LTBP1 which
lacks the 12th EGF-like repeat. Furthermore, sequencing of
genomic clones showed that splicing to generate LTBP1L occurs
using an intra-exonic 3P splice acceptor site in the first coding
exon of LTBP1S and that LTBP1v55 arises from the alternative
use of an exonic 3P splice acceptor site at the end of the following
intron. LTBP1v41 arises from skipping the exon which encodes
the 12th EGF-like repeat. LTBP1v55 and LTBP1v41 mRNA
are expressed in a wide variety of human tissues but the
proportions of each splice form vary in the tissues.
z 1998 Federation of European Biochemical Societies.
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1. Introduction
Transforming growth factor L (TGFL) is a widely expressed
cytokine that in£uences the growth and di¡erentiation of
many cell types [1^4]. In addition to important roles in normal
physiology, TGFL has been implicated in several pathological
conditions including atherosclerosis [5,6], ¢brosis [7] and some
cancers [8^10]. TGFL is secreted from cells as part of small
(V100 kDa) or large (V270 kDa) latent complexes from
which the active protein can be released. The small latent
complex consists of the mature TGFL homodimer (V25
kDa) non-covalently associated with the latency-associated
peptide (LAP, the amino-terminal remnant of the TGFL pre-
cursor) and association of LAP with mature TGFL is su⁄-
cient to confer latency. The large latent complex consists of
the small latent complex disul¢de-bonded to a latent TGFL
binding protein (LTBP).
To date four LTBP genes have been cloned (LTBP1,
LTBP2, LTBP3 and LTBP4) that encode proteins sharing
approximately 40% sequence homology. This family of pro-
teins appears to be closely related to the ¢brillins in that its
members contain long, tandem arrays of EGF-like repeats
and a novel eight-cysteine repeat of unknown function [11].
Some of the EGF-like domains contain a consensus calcium
binding sequence and calcium binding has been shown to
confer resistance to proteolysis on ¢brillin [12] and LTBP1
[13]. The third eight-cysteine repeat in LTBP1 contains a pu-
tative N-glycosylation site, and is necessary and su⁄cient for
the covalent interaction with the small latent complex of
TGFL [14,15].
In some cell types LTBP1 may be necessary for the normal
assembly and secretion of TGFL [16] although other cells have
been shown to secrete the small latent complex of TGFL [17].
In addition, several studies have suggested that LTBP plays a
role in regulating the activity of TGFL. For example, addition
of excess free LTBP, a peptide fragment of LTBP, or an anti-
body directed against native platelet LTBP inhibits TGFL
activation in a dose-dependent manner [18^20]. LTBP1 has
also been shown to associate with the extracellular matrix
(ECM) in vivo and in vitro [21^24]. These observations have
led to the suggestion that LTBP1 is a component of the ECM.
However, it is also possible that the role of the interaction
between LTBP1 and the ECM is to localise TGFL. Immuno-
histochemistry and in situ hybridisation experiments have
shown LTBP1 levels to be altered in certain pathological con-
ditions, including some cancers, although the role of LTBP1
in these diseases remains to be determined [25^32].
LTBP1 puri¢ed from di¡erent cell types varies in molecular
weight from 125 kDa in platelets to 190 kDa in ¢broblasts
[11,33]. Northern analysis has shown that most tissues express
two isoforms of LTBP1 mRNA, a shorter 5.2 kbp mRNA
(LTBP1S) and a longer 7.0 kbp mRNA (LTBP1L) [34].
LTBP1L mRNA encodes an additional 346 amino acids and
the LTBP1L protein has a greater a⁄nity for the ECM than
LTBP1S [34]. In addition to these two forms of LTBP1, we
and others have recently described a form of LTBP1 mRNA
(LTBP1v53) which encodes a protein that lacks 53 amino
acids including the eighth cysteine of the ¢rst cysteine repeat
and a consensus heparin binding sequence [35,36]. Alternative
splicing or post-translational modi¢cations may therefore ac-
count for some of the variations in the molecular weight of
LTBP1 protein. In this study we have analysed LTBP1
mRNA to determine other regions of the LTBP1 message
which can be alternatively spliced.
2. Materials and methods
2.1. Human tissue samples
Human heart, aorta and lung specimens were obtained during heart
and lung transplantation at Papworth Hospital (Cambridge, UK),
immediately frozen in liquid nitrogen and stored at 380‡C until an-
alysed. Human spleen, liver, gall bladder, cervix, ovary, tonsil, fore-
skin and veins were obtained from Addenbrooke’s Hospital (Cam-
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bridge, UK) surgical tissue bank. Normal human breast epithelial cells
were provided by Dr. Mike O’Hare, Department of Surgery, Univer-
sity College/Middlesex Medical School, London.
2.2. RNA and DNA manipulations
Total RNA was extracted from normal human tissues using the
RNeasy kit (Qiagen) according to the manufacturer’s instructions.
Three micrograms of total RNA was reverse transcribed as previously
described [35]. The PCR products were separated by electrophoresis
using a 1.5% agarose gel and DNA was visualised by staining with
ethidium bromide. PCR products from the gel were puri¢ed using a
gel extraction kit (Qiagen) and cloned into pGem-T-Easy vector
(Promega). DNA sequencing was performed using the ABI Prism
automated DNA sequencer using the dye terminator procedure.
Southern blot analysis, library screening, short-range PCR and
long-range (LR) PCR with plasmid DNA, cDNA and cosmid DNA
were carried out as previously described [35]. A human chromosome 2
cosmid library (LL02NC02) on stamped ¢lters was obtained from the
UK HGMP Resource Center and was screened by hybridisation to a
32P-labeled 924 bp PCR product from primer pair B (Fig. 1). For
Southern analysis, 32P-labeled probes were made using PCR products
from primers 10F and 2R, and 6F and 18R, as described above, for
detecting LTBP1v55 and LTBP1v41, respectively.
2.3. Numbering of LTBP1 sequence
The ¢rst base of LTBP1L cDNA (accession number L48925) is
de¢ned as base 1 (Fig. 1). The longer form of LTBP1 therefore con-
tains a coding sequence of 5166 bases. The LTBP1S message (acces-
sion number M34057) contains 145 bases not present in the LTBP1L
sequence, designated S1^S145 (Fig. 3a).
3. Results
3.1. Identi¢cation of alternatively spliced LTBP1 mRNA
To identify alternatively spliced forms of the LTBP1 gene,
RNA was isolated from human aorta and human breast epi-
thelial cells. This RNA was reverse transcribed using random
hexamers and ampli¢ed using ¢ve primer pairs (1^5 refer to a
forward and a reverse primer, Table 1) designed to amplify
overlapping fragments covering bases 151^5266 of LTBP1
(Fig. 1).
Primer pair 2 generated three products of 924 bp, V890 bp
and 756 bp (Fig. 2, lane 1). The sequence of the largest frag-
ment was identical to the corresponding region of the
LTBP1L sequence described by Olofsson et al. [34] while
that of the shortest lacked bases 1037^1204, suggesting that
the mRNA was alternatively spliced. We de¢ne the form of
LTBP1 mRNA with this deletion as LTBP1v55. When the
fragment of intermediate size (V890 bp) was cloned, the se-
quence obtained corresponded only to either the 924 bp or the
756 bp fragment. Mixing the puri¢ed DNAs of the large and
small fragments followed by PCR in the absence of Taq poly-
merase produced a gel pattern identical to that of the RT-
PCRs, indicating that the middle fragment was a heteroduplex
of the other two products (data not shown).
Primer pair 3 also produced three bands consistent with
splicing to generate LTBP1 and LTBP1v53, as previously
described, in addition to the formation of another heterodu-
plex which was con¢rmed by sequencing. Primer pair 4
produced two products, one of the expected size (V2400
bp) and one about 150 bp shorter. These fragments were
cloned into pGem-T-Easy and sequenced. The 3P and 5P se-
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Fig. 1. Regions of LTBP1 ampli¢ed to identify alternatively spliced forms. Schematic representation of the LTBP1 proteins LTBP1L and
LTBP1S. The dashed line represents the mRNA and the solid lines above show the regions of mRNA ampli¢ed by primer pairs 1^5. Primers
are labeled F for forward and R for reverse. The LTBP1 mRNA is numbered as described in Section 2.
Table 1
Primer sequences used
Primer Sequence
1F 5P-TCTTCGCGGACATTCAACGTCGCGCTCAAC-3P
1R 5P-ACGAGGTGTCCTGGGCAGCTATTGTTTC-3P
2F 5P-CCTAGCTGTGTTCCGCCATGTCAGAATG-3P
2R 5P-CTGGACAGGAAGCCCTTGGTACGAGACTTG-3P
3F 5P-CAAGGTGTATGCCCTAATGGTGAGTGTTTG-3P
3R 5P-CTCACTGGCCATAAATCCTGCTGGGCAAATG-3P
4F 5P-CGCAGGCCAATCCATCACCATGTAGGTAAAG-3P
4R 5P-GCTACACACGTATTCATCACTCAGATGTTC-3P
5F 5P-GCGGCATCCTCAATGGATGTGAAAATG-3P
5R 5P-GCCACACCTATCGGGCTCATCCTAAATC-3P
6F 5P-GCAAGGGGAGTGCCTAAACACAGAG-3P
7F 5P-CACTGTTTGTGACAGTCACGGGTTTTGTGAC-3P
8R 5P-CCTGGGGCTTGAAAGCCCTGATAACAGAG-3P
9R 5P-CAGGAAGGACCCTTCCACGTTTTCACAGAAG-3P
10F 5P-CAGGAGAGCAGTCCACTGAAGGTTC-3P
11R 5P-AAGGGAAAGAACCTTCAGTGGACTGCTCTC-3P
12F 5P-CCTTCCAAGGCAAGTTCATGGATACTAAGCTG-3P
13R 5P-GTGGTGTTCCCCTCCTCACAGCTGTTC-3P
14F 5P-GTAAAGTGACCTGCACCAAGGGCAGCTG-3P
15F 5P-CCATGGTGCCAGCGTGCCTAAACTTTATC-3P
16R 5P-GCTAGTCACGGTCAGAGGCAAGGTATGTGTTG-3P
17F 5P-CAACCAGGCCAATCCCAAGTCTCGTACCAAG-3P
18R 5P-CCACCAGCTTCAGAAGTAGATTCTCCAG-3P
Fig. 2. PCR products of LTBP1 cDNA from human lung tissue.
RNA was extracted from human lung tissue, reverse transcribed
and ampli¢ed as described in Section 2. Lane 1: LTBP1 and
LTBP1v55 ampli¢ed using primers 10F and 2R (Table 1). Lane 2:
LTBP1 and LTBP1v41 ampli¢ed using primers 6F and 18R. Lane
3: 100 bp ladder. The middle band in lanes 1 and 2 is a heterodu-
plex of the outer two bands.
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quences of both clones were identical to those of LTBP1
cDNA (M34057) indicating that the shorter fragment had
an internal deletion. Comparison of this region of LTBP1
cDNA with the Unigene EST database (Unigene code
HS.119574) identi¢ed cDNA clones AA522895 and
AA056948 which have bases 3731^3856 deleted. Therefore
four new primers (6F, 7F, 8R and 9R, Table 1) were synthe-
sised and used for PCR and sequencing of the long and short
clones. In addition to the expected products, PCR using prim-
ers 6F and 18R produced an intermediate-sized fragment
which was also con¢rmed to be a heteroduplex by sequencing
(Fig. 2, lane 2). Sequencing from primers 6F, 7F, 8R and 9R
showed that the shorter clone we had identi¢ed was identical
to the above EST sequences. The amino acid sequence en-
coded by bases 3731^3856 is the 12th EGF-like repeat in
LTBP1L and we de¢ne the form of LTBP1 with this deletion
as LTBP1v41. Primer pairs 1 and 5 both produced single
products which were of the expected size and sequence, indi-
cating that alternative splicing does not occur in these regions
of LTBP1 mRNA in breast epithelial cells and human aorta
examined here.
3.2. Genomic con¢rmation of the corresponding LTBP1v55
and LTBP1v41 cDNA
To con¢rm the cDNA data which suggested LTBP1v55 and
LTBP1v41 as new forms of LTBP1 mRNA, genomic struc-
tures of the relevant regions were de¢ned. A chromosome 2
cosmid library was screened with the radioactively labeled 924
bp PCR product from primer pair 2. Ten cosmids were iso-
lated (AE70c1, AE39g13, AE58m17, AE76g21, AE76g19,
AE31a24, AE26c8, AE28n16, AE32o19, and AE23d3) and
restriction endonuclease digests indicated genomic inserts to
range from 40 to 50 kbp.
Southern analysis and PCR (both short- and long-range)
were used to map the cosmid inserts and to select four cos-
mids covering bases 867^1704 of the cDNA sequence. Se-
quencing cosmid AE31a24 with primers 10F and 11R showed
that bases 867^1036 form a discrete exon (Figs. 3a and 4).
Sequencing of this cosmid from primer 12F did not produce a
product suggesting that this cosmid does not contain the bases
S1^S145. LR-PCR of human genomic DNA using primers
10F and 13R produced a product of V20 kbp.
Sequencing cosmid AE23d3 with primers 12F, 13R and 14F
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Fig. 3. Intron/exon structure of the LTBP1 gene in the regions spliced to generate LTBP1v55 and LTBP1v41. a: Nucleotide positions of the
four exons of LTBP1 are shown as de¢ned in Section 2. LTBP1L: exon W is joined to exon X through the use of an intra-exonic 3P splice ac-
ceptor site. LTBP1v55: exon X is omitted. LTBP1S: bases S1^S145 (the 5P untranslated region and signal peptide) are included in exon X.
b: LTBP1: exon 12E included. LTBP1v41: exon 12E omitted. The asterisks represent putative N-glycosylation sites.
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showed that bases S1^S145 and 1037^1204 are in the same
exon and comparison of the genomic DNA sequence with the
cDNA sequence data shows that the long LTBP1 message is
formed by the use of an intra-exonic splice junction (Figs. 3a
and 4). This intra-exonic splice acceptor site is 3P to the pu-
tative signal peptide sequence cleavage site of LTBP1S. Se-
quencing cosmids AE39g13 and AE32o19 with primers 2R,
15F, 16R, and 17F showed that bases 1205^1429 and 1430^
1704 form discrete exons. Comparison of these data with the
cDNA sequences shows that the shorter form of LTBP1L is
formed by use of the 3P splice acceptor site at the end of the
intron separating nucleotides 1204 and 1205. LR-PCR using
primers 2R, 14F, 15F and 16R showed that aV19 kbp intron
separates exons X and Y and that a V1.7 kbp intron sepa-
rates exons Y and Z (Fig. 3a).
To de¢ne the genomic structure of the cDNA forms ob-
tained from PCR with primer pair 4, human genomic DNA
was ampli¢ed by LR-PCR from primers 6F and 8R, and 7F
and 9R. These reactions produced products of V20 kbp and
V4.5 kbp. Direct sequencing of the genomic ampli¢cation
product from primers 7F and 9R showed that nucleotides
3856 and 3857 were in adjacent exons separated by a
4.5 kbp intron (Figs. 3b and 4). Alignment of the EST se-
quences and the sequences presented here, in conjunction with
the LR-PCR data, indicates that nucleotides 3730 and 3731
are in adjacent exons separated by a 20 kbp intron.
3.3. Tissue distribution of the corresponding RNA for
LTBP1v55 and LTBP1v41
To determine the tissue-speci¢c expression of the spliced
variants, RNA was isolated from a series of human tissues
and reverse transcribed using random hexamers. The cDNA
generated was ampli¢ed with primers 10F and 2R, and prim-
ers 6F and 18R to show the expression pattern for LTBP1v55
and LTBP1v41 DNA, respectively, and Southern blotted.
Southern blot analysis show both splice variants to be widely
expressed in human tissues in varying proportions. LTBP1v55
is most strongly expressed in lungs, breast epithelial cells,
cervix, ovaries and tonsils (Fig. 5). LTBP1v41 is the minor
form in most tissues but is the predominant form in heart
muscle (Fig. 6).
4. Discussion
The data presented de¢ne two further alternative splices in
the LTBP1 gene and show the genomic structure in the vicin-
ity of the splice sites. One region which can be alternatively
spliced generates two forms of LTBP1L. In the longer form,
splicing joins nucleotides 1036 and 1037 of LTBP1L cDNA
using a 3P splice acceptor site within the ¢rst coding exon of
LTBP1S (Fig. 3a). The shorter form of LTBP1L (LTBP1v55)
joins nucleotides 1036 and 1205 of the cDNA and uses the
splice acceptor site at the 3P end of the intron following the
¢rst coding exon of LTBP1S. Intra-exonic splicing normally
occurs when there are two possible (C/T)AG sequences close
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Fig. 4. Intron/exon boundaries of exons W, X, Y, Z, 12E-3P end and 13E-5P end. Intron sequences are in lower case and exon sequences are in
capitals. The sequence in bold for exon X encodes part of the LTBP1S signal peptide and is the intra-exonic 3P splice acceptor used to generate
LTBP1L. Exon sizes are in bp.
Fig. 5. Expression pattern of LTBP1 and LTBP1v55. RNA was iso-
lated from human tissues, reverse transcribed, ampli¢ed using prim-
ers 10F and 2R and the product detected by Southern analysis us-
ing an LTBP1 DNA probe.
Fig. 6. Expression pattern of LTBP1 and LTBP1v41. RNA was iso-
lated from human tissues, reverse transcribed, ampli¢ed using prim-
ers 6F and 18R and the product detected by Southern analysis us-
ing an LTBP1 DNA probe.
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together (e.g. as described for rat pro-opiomelanocortin
[37]). However, as in LTBP1v53, there is another complete
splice acceptor site within the coding sequence for LTBP1S
[35]. The amino acids deleted in LTBP1v55 encode two N-
glycosylation sites, identi¢ed by sequence homology. The
functional signi¢cance of these alternative forms remains to
be elucidated.
The other region in which we observed alternative splicing
contains the tandem EGF-like repeats. In the long form of the
mRNA, nucleotides 3730 and 3731 are joined whereas in the
shorter form nucleotides 3730 and 3857 are joined. The ge-
nomic structure de¢ned by PCR and sequencing from human
genomic DNA showed that nucleotides 3731^3856 form a
discrete exon and this exon is skipped in the short form of
the mRNA. These nucleotides code for a single EGF-like
repeat (the 12th EGF-like repeat of LTBP1) which contains
a consensus calcium binding site and a putative N-glycosyla-
tion site.
EGF-like repeats have been shown to be important in pro-
tein-protein interactions. For example, deletion mutagenesis
of Notch, a receptor involved in cell fate determination, iden-
ti¢ed two EGF-like repeats which are necessary and su⁄cient
for binding the Notch ligands Delta and Serrate [38]. The
interaction between protein S and complement C4b-binding
protein [39] and the ¢bronectin binding sites of ¢bulin-1 [40]
have also been mapped to calcium binding EGF-like repeats.
In addition, calcium binding to EGF-like repeats in ¢brillin
and LTBP1 stabilises the proteins and protects them from
proteolysis [12,13]. There are several examples where loss of
an EGF-like repeat occurs through splicing [41^43]. Although
an altered function for these proteins has been suggested, the
functional e¡ects of deleting an exon encoding an EGF-like
repeat is still unclear. However, mutations that cause skipping
of exons containing EGF-like repeats in the ¢brillin gene can
cause a severe form of the connective tissue disorder Marfan’s
syndrome [44]. LTBP1, which is structurally similar to ¢bril-
lin, has been suggested to be an ECM-associated protein [21^
23]. It is therefore possible that loss of the EGF-like repeat in
LTBP1v41 alters the protein-protein interactions of LTBP1,
resulting in a di¡erent function or localisation for this form of
the protein.
In conclusion, we have described two new alternative splices
of the LTBP1 gene, LTBP1v55 and LTBP1v41, and showed
their expression pattern in human tissues. Whether these trun-
cated forms of the LTBP1 protein have functions in TGFL
activation or LTBP localisation, and whether their expression
is correlated with disease remains to be determined.
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